Cara Therapeutics reports that it has earned a total of $2.5 million in milestone payments under its development and licensing agreements with Maruishi Pharmaceutical Company, Ltd. of Japan and Chong Kun Dang (CKD) Pharmaceutical Corp. of South Korea.

“We are very pleased with the rapid progress that the Maruishi team has made in moving into Phase 2 studies with I.V. CR845 in uremic pruritus,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.

Cara Therapeutics is a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.